DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville, MD 20857

ANDA 78-052

Abraxis Pharmaceutical Products
A Division of Abraxis BioScience, Inc.
Attention: Georgia Hizon
Regulatory Scientist
6133 North River Road, Suite 500
Rosemont, IL 60018

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 15, 2005, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Fosphenytoin Sodium Injection USP, 50 mg PE/mL (75 mg/mL), packaged in 100 mg PE/2 mL, and 500 mg PE/10 mL single-dose vials. [PE = phenytoin sodium equivalents].

Reference is also made to your amendments dated May 8, 2006; and May 14, 2007.

We have completed the review of this ANDA and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the ANDA is approved. The Division of Bioequivalence has determined your Fosphenytoin Sodium Injection USP, 50 mg PE/mL (75 mg/mL), to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Cerebyx Injection, 50 mg PE/mL (75 mg/mL), of Parke Davis.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Sincerely yours,

{See appended electronic signature page}

Gary Buehler
Director
Office of Generic Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Gary Buehler

8/6/2007 12:19:00 PM